0
0
Washington, D.C., May 14, 2025 – In a significant update to travel and vaccination guidance, US health officials have advised elderly individuals to avoid receiving the chikungunya vaccine, Ixchiq, following reports of serious adverse events, including heart and brain-related complications and two deaths globally.
Rising Chikungunya Cases Prompt Initial Vaccine Push
Chikungunya, a mosquito-borne viral disease characterized by fever and severe joint pain, has seen a surge in cases across several regions, notably in France’s Indian Ocean territories. La Reunion alone has reported over 47,000 cases and 12 deaths as of early May 2025, prompting health authorities to recommend vaccination, especially for frequent travelers and those at higher risk.
CDC Issues New Advisory After Adverse Events
The Centers for Disease Control and Prevention (CDC) initially supported the use of Valneva’s Ixchiq vaccine to curb the spread. However, following reports of severe adverse reactions-particularly in elderly recipients with pre-existing health conditions-the CDC has now urged older adults to refrain from taking the vaccine. Adverse events, including heart and brain complications, were observed within a week of vaccination, raising alarm among health officials.
The European Medicines Agency (EMA) has also temporarily suspended the use of Ixchiq in adults aged 65 and above, pending further investigation. The French government has similarly halted its use after the deaths of two elderly adults, aged 62 and 89, were reported post-vaccination. The exact link between the vaccine and these fatalities is still under review.
Alternative Vaccine Recommended
In light of these developments, US advisors have recommended Bavarian Nordic’s Vimkunya vaccine for individuals above 12 years of age as a safer alternative. Travelers, particularly pregnant women, are also being advised to reconsider trips to affected regions due to the risk of mother-to-child transmission of the virus.
Ongoing Investigations and Public Health Guidance
Both US and European regulators are conducting thorough investigations to determine the safety profile of the Ixchiq vaccine in elderly populations. Meanwhile, public health authorities continue to emphasize the importance of mosquito control and personal protection measures to prevent chikungunya infection.
Disclaimer:
This article is based on information available as of May 14, 2025, and is intended for informational purposes only. The situation regarding chikungunya vaccination and related advisories is evolving. For the latest guidance, consult official sources such as the CDC, WHO, or your healthcare provider. The link between the Ixchiq vaccine and reported adverse events is still under investigation, and recommendations may change as new data emerges.
Citations:
